Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23797245 | 0.88 | MAPT (0.39) | MAPTTDP1CA12CA2CA14 | |
| SCHEMBL13201422 | 0.87 | MAPT (0.43) | MAPTDGAT1CYP2C19TDP1POLB | |
| SCHEMBL14014467 | 0.83 | MAPT (0.39) | MAPTDGAT1CA2 | |
| SCHEMBL13201403 | 0.80 | MAPT (0.46) | MAPTDGAT1CYP2C19TDP1POLB | |
| SCHEMBL7398035 | 0.80 | MAPT (0.46) | MAPTDGAT1CYP2C19TDP1POLB | |
| SCHEMBL8225007 | 0.78 | MAPT (0.52) | MAPTCYP2C19TDP1POLBCA12 | |
| SCHEMBL23797497 | 0.76 | MAPT (0.38) | MAPTCYP2C19TDP1CA12CA2 | |
| SCHEMBL1730377 | 0.76 | MAPT (0.38) | MAPTTDP1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL6062373 | 0.76 | MAPT (0.38) | MAPTTDP1CA2KDM4ESMN1; SMN2 | |
| SCHEMBL31346359 | 0.74 | DGAT1 (0.45) | MAPTDGAT1TDP1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3876928-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-12-30 | — | — | US | disclosed |
| EP-3876928-A2 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403479-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC3 | MAPT 2491/4885DGAT1 3738/4885CYP2C19 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.